“We are pleased with the pace and execution of our RAS-targeting franchise and its early entry into the clinic following the recent IND clearance for ERAS-0015 and IND filing for ERAS-4001,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “Importantly, both product candidates have demonstrated differentiated therapeutic potential in multiple preclinical models and may have broad application across significant areas of unmet medical need for patients, including in colorectal, pancreatic, and non-small cell lung cancers. We look forward to advancing clinical development of these exciting programs with initial monotherapy data for both expected in 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca announces IND clearance, prioritizing of RAS-targeting franchise
- Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating
- Erasca presents new RAS-targeting franchise data at AACR meeting
- Erasca initiated with an Outperform at Raymond James
- Erasca’s Innovative RAS Platform: A Buy Rating for Potential Best-in-Class Therapeutics